FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>GAITHER JAMES C</u>						2. Issuer Name and Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT]								5. Relati (Check a		olicable)	rting Person(s)		o Issuer 6 Owner	
(Last) 755 PAG		(First)	(I D, SUITE A-2	Middle)			f Earlie: 005	st Trans	saction (Month/Day/Year)						Offic belov	er (give titl w)	le	Oth bel	er (specify ow)	
(Street) PALO Al	LTO	CA	9)430410	005	4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	ı	(State)) (2	Zip)												Pers		nore ur	an One F	ерогинд
			Tabl	e I - No	on-Deriv	ative	Sec	curitie	es Ac	quired	l, Dis	sposed o	f, or E	Benefi	cially O	wne	ed			
Date		Date	ransaction e onth/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a 5)			nd Securities Beneficially Owned Following		es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
										Code	v	Amount	(A) or (D) Price		Tra	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common	Stock				12/08/2	2005				J ⁽¹⁾		5,539	D	(L)	2,21	0,649		I	By Ltd Partnership (SHV) ⁽²⁾
Common	Stock															40,	605		D	
Common	Stock															22,	422		Ι	By Ltd Partnership (SHAI) ⁽³⁾
Common Stock												56,768			I	By Ltd Partnership (SHQP) ⁽⁴⁾				
			Та	ble II -								osed of, convertib				ned				
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, To Courity or Exercise (Month/Day/Year) if any			5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr.) and 4)		8. Price Derivati Security (Instr. 5)	tive ty	ive derivativ	e Over State of State	10. Ownersh Form: Direct (D or Indirec (I) (Instr.	Beneficial Ownership ct (Instr. 4)				
					Code		v	(A)	(D)			Expiration Date	Title	Amour or Numbe of Shares						

Explanation of Responses:

- 1. Distribution of shares without consideration to a retired Managing Director of the General Partner of Sutter Hill Ventures, A California Limited Partnership, in accordance with the partnership agreement.
- 2. Shares held by Sutter Hill Ventures, A California Limited Partnership. The reporting person is a Managing Director of the General Partner of Sutter Hill Ventures, A California Limited Partnership. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the partnership.
- 3. Shares held by Sutter Hill Entrepreneurs Fund (AI), L.P. The reporting person is a Managing Director of the General Partner of Sutter Hill Entrepreneurs Fund (AI), L.P. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the partnership.
- 4. Shares held by Sutter Hill Entrepreneurs Fund (QP), L.P. The reporting person is a Managing Director of the General Partner of Sutter Hill Entrepreneurs Fund (QP), L.P. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest in the partnership.

Remarks:

By: Robert Yin, by power of attorney

12/12/2005

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby authorizes David E. Sweet, Robert Yin, Patricia Tom, David L. Anderson, G. Leonard Baker, Jr., Tench Coxe, Gregory P. Sands, James N. White, or William H. Younger, Jr. to execute for and on behalf of the undersigned Forms 3, 4, and 5, and any Amendments thereto for Corcept Therapeutics, Incorporated ("the Company"), and cause such form(s) to be filed with the United States Securities and Exchange Commission pursuant to Section 16(a) of the Securities Act of 1934, relating to the undersigned's beneficial ownership of securities in the Company. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such a capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

In witness whereof, the undersigned has caused this Power of Attorney to be executed as of this 13th day of April, 2004.

/s/ James C. Gaither